Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients

• Main Authors: Kiran Godse (Author), Murlidhar Rajagopalan (Author), Mukesh Girdhar (Author), Sanjiv Kandhari (Author), Bela Shah (Author), Prashant N Chhajed (Author), Sushil Tahiliani (Author), D S Krupa Shankar (Author), Vijay Somani (Author), Vijay Zawar (Author)
• Format: Book
• Published: Wolters Kluwer Medknow Publications, 2016-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE antibodies and reduces the circulating levels of free...